Scale, quality, process control and the operational economics of producing medicines.
Merck–Moderna’s collaboration provides the timeline; a separate cash model tests option exercise, delay, settlement and the no-payment branch.
Vyxeos provides the clinical anchor; a separate yield and cash-cost model tests whether a manufacturing improvement deserves investment.
FDA’s 2026 terminology change, a historical liver-chip benchmark and a transparent error-cost model show what a validation investment must establish.
A discovery becomes a medicine through thousands of repeatable decisions. Step inside the less visible world that turns a promising result into reliable supply.
Follow the decisions between a promising result and completed care—and distinguish scientific failure from avoidable execution gaps.
A fictional day asks what earlier detection, personalized treatment, and connected care would need to deliver for a real person.
The CRISPR patent appeal frames a hypothetical rights map, licensing sensitivity and IP diligence gate.
Pfizer–Seagen provides transaction context for a fictional buyer’s integration reserve and portfolio gates.
![Announced 2023 collaboration payment categories. Upfront: 4; Continuation: 1.5; Maximum sales milestones: 16.5. USD billions. Three-asset deal [1]; contingent ceiling is not received cash.](/images/consulting/adc-license-headline-value-fundable-cash-record.svg)
A major ADC collaboration and a recent filing setback frame staged licensing, dilution and evidence-linked funding.
![Reported cardiovascular event proportions. Wegovy: 6.5; Placebo: 8. Participants with event (%). FDA 2024 announcement [1]; absolute difference 1.5 percentage points.](/images/consulting/wegovy-outcomes-evidence-access-dossier-record.svg)
Wegovy’s outcomes result and Medicare’s next negotiation cycle frame evidence, budget and eligible-population planning.
Repatha’s historical reset and recent growth provide context for a fictional launch team’s break-even calculation.
Sovaldi and current Medicare pricing implementation frame an indication-specific budget-impact assignment.
Genzyme’s remediation history anchors a hypothetical outage-exposure and backup-capacity decision.
A historical gene-therapy data issue informs a hypothetical audit, remediation and transaction-delay model.
Kymriah and current cell-therapy commercialization frame manufacturing reliability, release timing and patient readiness.
![Original Casgevy study: retain the denominators. Treated: 44; Efficacy evaluable: 31; Met VF12 endpoint: 29. Patients. 2023 FDA review [1]; nested groups, not independent cohorts.](/images/consulting/casgevy-treatment-center-capacity-economics-record.svg)
Original gene-editing evidence and 2026 launch revenue inform a hypothetical treatment-center capacity model.
The Elevidys safety revision informs a hypothetical surveillance budget and an eligibility-sensitive operating plan.
![Original tissue-agnostic evidence: one bounded response estimate. Objective response: 39.6. Response (%). 149 patients across five trials [1]; not a required ADC response threshold.](/images/consulting/adc-phase-two-response-filing-runway-record.svg)
A September 2026 ADC filing withdrawal becomes a hypothetical evidence-gap, delay and cash-runway assignment.
Coordinate clinical, regulatory and manufacturing decisions with clear ownership, acceptance criteria and measurable handoffs.
A numerical framework for understanding why a milestone may change value—and why the calendar alone does not.
Turn a leadership directory into a dated, evidence-based partnering process with measurable progression.
Historical financing events and a runway model clarify what a capital headline can—and cannot—tell a reader.
A MASH case shows why a biomarker result, an approval and a commercial forecast answer different questions.
Positive and negative trial examples show why endpoint choice, patient selection and execution costs must be assessed together.
A large ADC collaboration illustrates why maximum announced consideration should be decomposed before it enters a value narrative.
Historical transition rates help frame the challenge; the program’s evidence must determine the actual go, revise, or stop decision.
A corrected public cost study shows why a headline R&D estimate is a starting point for analysis, not a universal budget or price justification.
Recent FDA prevention counts provide a signal about supply interventions, while leaving product-level access questions unresolved.
A small Phase I study provides a useful early signal and a clear boundary around what remains to be demonstrated.
A randomized breast-cancer trial shows why efficacy and adverse-event context belong in the same product discussion.
Two randomized trials illustrate how to communicate a strong biomarker result without extending it beyond the measured outcome.
Dendreon’s 2010–2014 record separates clinical value, operating revenue, and financing resilience.
A historical storage change shows why a process convenience needs product-specific supporting data.
APOLLO joined a molecular mechanism to 18-month clinical measures in a defined hereditary disease.
The CMS access model makes outcome contracting, treatment logistics, and follow-up separate milestones.